Werewolf Therapeutics, Inc. HOWL 深 滬
已收盤 06-18 16:00:00 美东时间
0.3513
+0.007
+2.12%
華盛通- 最 高0.3799
- 今 開0.3571
- 成交量 157.58万股
- 最 低 0.3425
- 昨 收 0.344
- 總市值 1707.21万
- 52周最高 2.38
- 市盈率 靜 --
- 換手率 3.24%
- 52周最低 0.338
- 委 比 0.00%
- 總股本 4859.68万
- 歷史最高 23.99
- 量 比 1.88
- 振 幅 10.87%
- 歷史最低 0.338
- 每 手 1
- 風險率 0.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why e.l.f. Beauty Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket
Shares of elf Beauty Inc (NYSE: ELF) rose sharply in pre-market trading after beating analyst expectations with fourth-quarter earnings of 32 cents per share and revenue of $449.29 million, up 35%. Other pre-market gainers include WHLR, ATPC, LIMN, JUNS, ILLR, NCPL, VIDA, WNW, and APLD. The biggest losers are WGRX, MMA, IPW, and CAPS.
05-21 17:21
Werewolf Therapeutics Q1 EPS $(0.28), Inline
Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.28) per share which met the analyst consensus estimate. This is a 30 percent increase over losses of $(0.40) per share from the same period last year.
05-08 04:45
Earnings Scheduled For March 27, 2026
Companies Reporting Before The Bell • Instil Bio (NASDAQ:TIL) is expected to re...
03-27 19:11
Werewolf Therapeutics Q4 net loss narrows as expenses fall
Werewolf Therapeutics Q4 net loss narrows as expenses fall Overview US biopharmaceutical firm's Q4 net loss narrowed yr/yr Operating expenses for Q4 declined compared to prior year Company initiated process to explore strategic alternatives including sale of assets or merger Outlook Werewolf Therape
03-27 19:10
Werewolf Therapeutics Q4 EPS $(0.20) Beats $(0.35) Estimate
Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.35) by 43.18 percent. This is a 56.52 percent increase over losses of $(0.46) per share
03-27 19:02
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
Werewolf Therapeutics announced a strategic review to maximize shareholder value, exploring options like sale, merger, or partnerships, with Piper Sandler as advisor. Q4 and 2025 financials showed cash of $57.1M, reduced R&D and G&A expenses, and narrowed net loss to $8.4M from $20.4M. Strategic alternatives are under consideration without a set timeline.
03-27 11:00
Werewolf Therapeutics Begins Strategic Alternatives Review Process
Werewolf Therapeutics ( ($HOWL) ) has shared an announcement. On February 24, 2...
02-25 07:22
Werewolf Therapeutics shares are trading higher after the company announced plans to explore strategic alternatives.
Werewolf Therapeutics shares are trading higher after the company announced pla...
02-25 05:38
Werewolf Therapeutics Mulls Strategic Options
Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the "Company" or "Werewolf"), an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the
02-25 05:12
Werewolf Therapeutics Receives Nasdaq Minimum Bid Price Notice
An announcement from Werewolf Therapeutics ( ($HOWL) ) is now available. On Feb...
02-07 06:00
